148 related articles for article (PubMed ID: 10647667)
1. The perioperative charge equivalence of interstitial brachytherapy and radical prostatectomy with 1-year followup.
Kohan AD; Armenakas NA; Fracchia JA
J Urol; 2000 Feb; 163(2):511-4. PubMed ID: 10647667
[TBL] [Abstract][Full Text] [Related]
2. Charge and length of hospital stay analysis of radical retropubic prostatectomy and transperineal prostate brachytherapy.
Wagner TT; Young D; Bahnson RR
J Urol; 1999 Apr; 161(4):1216-8. PubMed ID: 10081872
[TBL] [Abstract][Full Text] [Related]
3. Comparison of radical prostatectomy and iodine 125 interstitial radiotherapy for the treatment of clinically localized prostate cancer: a 7-year biochemical (PSA) progression analysis.
Polascik TJ; Pound CR; DeWeese TL; Walsh PC
Urology; 1998 Jun; 51(6):884-9; discussion 889-90. PubMed ID: 9609622
[TBL] [Abstract][Full Text] [Related]
4. A nationwide charge comparison of the principal treatments for early stage prostate carcinoma.
Brandeis J; Pashos CL; Henning JM; Litwin MS
Cancer; 2000 Oct; 89(8):1792-9. PubMed ID: 11042575
[TBL] [Abstract][Full Text] [Related]
5. 103Pd brachytherapy versus radical prostatectomy in patients with clinically localized prostate cancer: a 12-year experience from a single group practice.
Sharkey J; Cantor A; Solc Z; Huff W; Chovnick SD; Behar RJ; Perez R; Otheguy J; Rabinowitz R
Brachytherapy; 2005; 4(1):34-44. PubMed ID: 15737905
[TBL] [Abstract][Full Text] [Related]
6. Update on Memorial Sloan-Kettering Cancer Center studies of neoadjuvant hormonal therapy for prostate cancer.
Fair WR; Betancourt JE
Mol Urol; 2000; 4(3):241-8;discussion 249-50. PubMed ID: 11062380
[TBL] [Abstract][Full Text] [Related]
7. Surgery versus implant for early prostate cancer: results from a single institution, 1992-2005.
Colberg JW; Decker RH; Khan AM; McKeon A; Wilson LD; Peschel RE
Cancer J; 2007; 13(4):229-32. PubMed ID: 17762756
[TBL] [Abstract][Full Text] [Related]
8. Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years.
Amling CL; Blute ML; Bergstralh EJ; Seay TM; Slezak J; Zincke H
J Urol; 2000 Jul; 164(1):101-5. PubMed ID: 10840432
[TBL] [Abstract][Full Text] [Related]
9. Extended prostate biopsy scheme improves reliability of Gleason grading: implications for radiotherapy patients.
King CR; McNeal JE; Gill H; Presti JC
Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):386-91. PubMed ID: 15145152
[TBL] [Abstract][Full Text] [Related]
10. High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds.
Grills IS; Martinez AA; Hollander M; Huang R; Goldman K; Chen PY; Gustafson GS
J Urol; 2004 Mar; 171(3):1098-104. PubMed ID: 14767279
[TBL] [Abstract][Full Text] [Related]
11. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer.
Han M; Partin AW; Zahurak M; Piantadosi S; Epstein JI; Walsh PC
J Urol; 2003 Feb; 169(2):517-23. PubMed ID: 12544300
[TBL] [Abstract][Full Text] [Related]
12. Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects.
Gleave ME; Goldenberg SL; Chin JL; Warner J; Saad F; Klotz LH; Jewett M; Kassabian V; Chetner M; Dupont C; Van Rensselaer S;
J Urol; 2001 Aug; 166(2):500-6; discussion 506-7. PubMed ID: 11458055
[TBL] [Abstract][Full Text] [Related]
13. Relationship of biochemical outcome to percentage of positive biopsies in men with clinically localized prostate cancer treated with permanent interstitial brachytherapy.
Guzzo TJ; Levin BM; Lee R; Guo M; Chen Z; Whittington R; Tomaszewski J; Malkowicz SB
Urology; 2008 Apr; 71(4):723-7. PubMed ID: 18387401
[TBL] [Abstract][Full Text] [Related]
14. Long-term outcomes in younger men following permanent prostate brachytherapy.
Shapiro EY; Rais-Bahrami S; Morgenstern C; Napolitano B; Richstone L; Potters L
J Urol; 2009 Apr; 181(4):1665-71; discussion 1671. PubMed ID: 19233394
[TBL] [Abstract][Full Text] [Related]
15. Brachytherapy for clinically localized prostate cancer: thirteen-year disease-free survival of 769 consecutive prostate cancer patients treated with permanent implants alone.
Ragde H; Grado GL; Nadir BS
Arch Esp Urol; 2001 Sep; 54(7):739-47. PubMed ID: 11692443
[TBL] [Abstract][Full Text] [Related]
16. An assessment of quality of life following radical prostatectomy, high dose external beam radiation therapy and brachytherapy iodine implantation as monotherapies for localized prostate cancer.
Frank SJ; Pisters LL; Davis J; Lee AK; Bassett R; Kuban DA
J Urol; 2007 Jun; 177(6):2151-6; discussion 2156. PubMed ID: 17509305
[TBL] [Abstract][Full Text] [Related]
17. No difference in six-year biochemical failure rates with or without pelvic lymph node dissection during radical prostatectomy in low-risk patients with localized prostate cancer.
Bhatta-Dhar N; Reuther AM; Zippe C; Klein EA
Urology; 2004 Mar; 63(3):528-31. PubMed ID: 15028451
[TBL] [Abstract][Full Text] [Related]
18. Pathological parameters of radical prostatectomy for clinical stages T1c versus T2 prostate adenocarcinoma: decreased pathological stage and increased detection of transition zone tumors.
Jack GS; Cookson MS; Coffey CS; Vader V; Roberts RL; Chang SS; Smith JA; Shappell SB
J Urol; 2002 Aug; 168(2):519-24. PubMed ID: 12131301
[TBL] [Abstract][Full Text] [Related]
19. Long-term outcome following radical prostatectomy in men with clinical stage T3 prostate cancer.
Carver BS; Bianco FJ; Scardino PT; Eastham JA
J Urol; 2006 Aug; 176(2):564-8. PubMed ID: 16813890
[TBL] [Abstract][Full Text] [Related]
20. Permanent 125I-seed brachytherapy or radical prostatectomy: a prospective comparison considering oncological and quality of life results.
Borchers H; Kirschner-Hermanns R; Brehmer B; Tietze L; Reineke T; Pinkawa M; Eble MJ; Jakse G
BJU Int; 2004 Oct; 94(6):805-11. PubMed ID: 15476513
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]